FMF Genotype-phenotype correlation in Iranian Azeri Turks: Association between M694V/R761H mutation and amyloidosis

Morteza Jabbarpour Bonyadi 1, Mohammad Hossein Somi 2, Mir Milad Pourmousavi Khoshknab 2, Forough Eslami 2, Mehrdad Montazam 2, Sousan Mir Najd Gerami 2*

1 Faculty of Natural Sciences, Center for Excellence in Biodiversity, University of Tabriz, Tabriz, Iran
2 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

**ABSTRACT**

**Objectives:** Familial Mediterranean fever (FMF), an inherited autosomal recessive disorder, is frequently present among individuals of Mediterranean origin. Differences in the clinical manifestations of FMF between different ethnic groups have been documented. The aim of the present study was to determine the most common characteristics of FMF and the relationship between clinical findings and the most common mutant alleles of the MEFV gene in an Iranian Azeri Turk population.

**Materials and Methods:** We analyzed clinical and genetic data from 415 patients identified as having FMF clinical symptoms and who were referred to the Molecular Genetics Laboratory of Tabriz/Iran over the last 3 years. The mutation type and clinical characteristics were determined for each patient.

**Results:** The following primary clinical characteristics of the patients were observed: peritonitis was observed in 378 (93.8%), high-grade fever in 351 (86.88%), arthritis in 215 (54.57%), pleuritis in 207 (53.49%), myalgia in 153 (41.69%), AA amyloidosis in 149 (40.16%), and erysipelas-like erythema in 54 (14.96%) subjects. A positive response to colchicines treatment was noted in 374 (95.1%) patients including 303 patients with two mutated alleles and 71 patients with one identified mutation.

**Conclusion:** In contrast to previous studies, there was no significant association between M694V mutation and development of amyloidosis. The M680I/M680I, M680I, M694I, and M694V/R761H genotypes were found to be associated with the development of amyloidosis. These results indicate that physicians need to pay careful attention to patients with asymptomatic or mildly symptomatic FMF with these genotypes.

**Keywords:** Amyloidosis, Familial Mediterranean fever, Iran, M694V/R761H

---

**Introduction**

Familial Mediterranean fever (FMF, MIM# 249100) is one of the most common autosomal genetic diseases. FMF primarily affects populations from the Mediterranean basin, especially Turks, Azeri Turks, Armenians, non-Ashkenazi Jews, and Arabs (1-4). It affects more than 100,000 people worldwide. FMF was first described in 1945 and the gene responsible for the disease, MEFV, was identified in 1992. MEFV is located on chromosome 16p13.3 and consists of 10 exons, which encode a protein of 781 amino acids named pyrin or marenostrin (5, 6). Pyrin is primarily expressed in granulocytes and is thought to be a negative regulator of inflammation (7, 8). Sets of criteria have been described for diagnosis of FMF. The most famous of these is Tel Hashomer’s criteria, which defines diagnosis based on the characterization of major and minor criteria (9).

Definitive diagnosis of FMF requires the fulfillment of two major criteria or one major and two minor criteria. Major criteria are: (a) typical attacks of peritonitis, pericarditis, or pleuritis, (b) fever alone, (c) recurrent febrile episodes accompanied by peritonitis, synovitis, or pleuritis, incomplete abdominal attacks, (d) amyloidosis of the AA type without predisposing disease, and (e) favorable response to continuous colchicines treatment. Minor criteria are: (a) Erysipelas-like erythema, (b) recurrent febrile episodes, (c) FMF in a first-degree relative, and (d) complete attacks involving the chest, joint, exertional leg pain, and (e) favorable response to colchicines. Peritonitis is the principal clinical finding of FMF associated with febrile episodes. It is experienced by the majority of patients and is reported as the first symptom in about half of them. The articular pain in FMF episodes is the second-most frequent symptom...
associated with fever and acute arthritis. Usually redness, warmth, tenderness, and swelling are also present. During FMF attacks, not only a developed acute-phase response occurs, but high levels of inflammatory mediators, such as interleukin-6 (IL-6), tumor necrosis factor–alpha (TNF-α), and serum amyloid-A (SAA) can also be found. Between recurrent and self-limited attacks of fever, severe abdominal, articular, and/or chest pain, patients with FMF are usually free of symptoms. Amyloidosis due to chronic inflammation leading to renal failure is the major complication of this disease. Colchicine is an oral drug used for preventing or treating attacks. Daily intake of colchicine (1–2 mg) has been the recommended treatment for FMF since its introduction in 1972 (10). Adherence to treatment results in a significant decrease in the frequency and severity of attacks, or prevents them in about 95% of patients. Since the cloning of the MEFV gene, about 180 mutations have been associated with FMF (11). M694V, V726A, E148Q, M694I, and M680I are the five most frequently encountered mutations and account for 74% of FMF mutations in typical patients (12). The rest of the mutations are very rare in different populations. Differences in clinical presentation of FMF among different ethnic groups have been studied. However, phenotype-genotype correlations in FMF have not been decisively resolved. The aims of this study were to find the most frequent mutation in a cohort of Iranian Azeri Turks with FMF and to investigate the effect of genetic factors on the phenotype, especially in terms of the development of amyloidosis in a population living in the North West of Iran.

Materials and Methods
This study was conducted in the FMF clinic of Medical University of Tabriz between April 2010 and April 2013. A total number of 415 patients were referred by gastroenterologists, rheumatologists, and pediatricians for diagnosis and genetic counseling regarding FMF. After obtaining Informed Consent from patients, personal and medical data were recorded. Diagnosis was done based on the Tel-Hashomer criteria. All patients were of Azeri Turks origin from the North West of Iran. Mean age was 26.0 ± 14.76 years with a range of 3–78 years and a male/female ratio of 1.30. DNA was isolated from peripheral blood lymphocytes by standard procedures and amplified with sequence-specific primers using PCR. Patients were screened for 10 MEFV gene mutations including M694V, V726A, E148Q, M680I, M694I, R761H, A744S, P369S, E167D, and R408Q. The presence of the M694V, V726A, M694I, M680I, R761H, E167D, and A744S mutations was determined using arms PCR and the accuracy of the PCR was verified by direct sequencing. The E148Q, R408Q, and P369S mutations were detected by PCR-restriction fragment length polymorphism methods. Genotype-phenotype correlation was investigated in 415 Turkish patients with FMF. The patients were grouped according to their mutations and main clinical parameters (fever, arthritis, peritonitis, and amyloidosis) and comparisons were made among the groups. We analyzed the genotype-phenotype correlation using Chi-square and Fisher’s exact tests. The SPSS software (version 16.0), VassarStat, and JavaStat websites (statpages.org/ctab2x2.html) were used for data analysis. The odds ratios (OR) and confidence intervals (CI) at 95% significance level were calculated for all data. The significance of the differences of observed genotypes between patients with or without a specific clinical symptom was tested using Chi square test and further comparison of confidence intervals. P-values less than 0.01 were considered statistically significant.

Results
In this study, five MEFV gene mutations (M694V, V726A, E148Q, M680I, and M694I) accounted for 95.52% of mutations. The most frequent mutation was M694V (42.05% of the alleles). The main clinical characteristics of 235 patients were as follows: peritonitis was observed in 378, fever in 351, arthritis in 215, pleuritis in 207, myalgia in 153, amyloidosis in 149, and erysipelas-like erythema in 54 subjects. A positive response to colchicine treatment was noted in 374 patients, including 303 patients with 2 mutated alleles and 71 patients with 1 mutation. A positive family history of FMF was observed in 103 of the patients, where at least one member of the family had FMF (Table 1). The mean age of onset in the homozygotes group was: 6.96 years for M694V, 10.75 years for E148Q, 22.87 years for V726A, and 14.38 years for M680I. The mean age of onset in the compound heterozygotes group was: 12.73 years for M694V, 13.10 years for E148Q, 11.08 years for V726A, and 12.96 years for M680I. The mean age of onset in the heterozygotes group was: 19.37 years for M694V, 13.02 years for E148Q, 12.32 years for V726A, and 13.95 years for M680I. The mean age of onset in the compound heterozygotes group was: 12.73 years for M694V, 13.10 years for E148Q, 11.08 years for V726A, and 12.96 years for M680I. The mean age of onset in the heterozygotes group was: 19.37 years for M694V, 16.85 years for E148Q, 18.12 years for V726A, and 27.87 years for M680I. Patients were categorized into three groups according to their allele status: homozygous, heterozygous, and compound heterozygous. In the

| Features                         | N=415 |
|---------------------------------|-------|
| Male/Female                     | 235/180|
| Age at onset                    | 15.59 |
| Peritonitis                     | 93.8  |
| Fever                           | 86.88 |
| Arthritis                       | 54.57 |
| Pleuritis                       | 53.49 |
| Myalgia                         | 41.69 |
| Erysipelas-like erythema        | 14.96 |
| Amyloidosis                     | 40.16 |
| Family history of FMF           | 24.88%|
| Response to colchicine treatment| 95.1  |
Table 2. Phenotype–genotype correlation in homozygote group

| Features                  | n=95     | M694V/M694V | V726A/V726A | E148Q/E148Q | M680I/M680I | M694I/M694I |
|---------------------------|----------|-------------|-------------|-------------|-------------|-------------|
| Fever With (%)            | 71.11    | 8.88        | 2.22        | 15.55       | 2.22        |
| Without (%)               | 40       | 0           | 0           | 40          | 0           |
| P value                   | <0.001   | <0.001      | <0.001      | 0.200       | <0.001      |
| Peritonitis Without (%)   | 75       | 0           | 25          | 0           |
| P value                   | 0.263    | <0.001      | <0.001      | 0.046       | <0.001      |
| Arthritis Without (%)     | 79.06    | 2.32        | 4.65        | 11.62       | 2.32        |
| P value                   | 0.002    | 0.002       | 0.302       | 0.052       | 0.275       |
| Amyloidosis Without (%)   | 78.43    | 7.84        | 3.92        | 7.84        | 1.96        |
| P value                   | <0.001   | 0.301       | 0.446       | <0.001      | 0.415       |

Table 3. Phenotype–genotype correlation in compound heterozygote group

| Features                  | n=129    | M694V/E148Q | M694V/V726A | M694V/M680I | M694V/R761H | V726A/M680I |
|---------------------------|----------|-------------|-------------|-------------|-------------|-------------|
| Fever With (%)            | 22.61    | 38.26       | 18.26       | 4.35        | 16.52       |
| Without (%)               | 28.57    | 35.71       | 28.57       | 0           | 25          |
| P value                   | 0.158    | 0.329       | 0.050       | <0.001      | 0.068       |
| Peritonitis Without (%)   | 23.58    | 36.59       | 19.51       | 4.06        | 16.26       |
| P value                   | 0.106    | <0.001      | 0.280       | <0.001      | <0.001      |
| Arthritis Without (%)     | 19.12    | 35.29       | 19.12       | 7.35        | 19.12       |
| P value                   | 0.091    | 0.222       | 0.515       | <0.001      | 0.043       |
| Amyloidosis Without (%)   | 27.12    | 37.29       | 22.03       | 1.69        | 11.86       |
| P value                   | 0.094    | 0.515       | 0.138       | 0.047       | 0.071       |

Table 4. Phenotype–genotype correlation in heterozygote group

| Features                  | n=154    | M694V       | V726A       | E148Q       | M680I       | M694I       |
|---------------------------|----------|-------------|-------------|-------------|-------------|-------------|
| Fever With (%)            | 30.77    | 17.95       | 40.17       | 11.11       | 0           |
| Without (%)               | 16.2     | 29.7        | 46          | 5.40        | 2.70        |
| P value                   | 0.009    | 0.018       | 0.230       | 0.047       | 0.152       |
| Peritonitis Without (%)   | 29.85    | 17.16       | 42.54       | 9.70        | 0.75        |
| P value                   | <0.001   | <0.001      | 0.139       | 0.395       | <0.001      |
| Arthritis Without (%)     | 25       | 22.37       | 44.73       | 11.84       | 0           |
| P value                   | 0.237    | 0.249       | 0.187       | 0.416       | <0.001      |
| Amyloidosis Without (%)   | 34.29    | 0.57        | 37.14       | 17.14       | 2.06        |
| P value                   | 0.071    | <0.001      | 0.235       | 0.011       | <0.001      |

Discussion

The results of previous mutation studies have led to the hypothesis that phenotypic variation of the disease may be attributable to the existence of some of these mutations. Correlation of the genotypes of patients with FMF with the various phenotypes of the disease, especially amyloidosis, has often been studied. However, there are few published studies conducted with Azeri Turk patients with FMF. To assess the phenotypic variation associated with the existence of particular mutations in Azeri Turk patients with FMF living in Iran, we discussed each genotype with the corresponding patient symptoms.

In our series from Iran, the age of onset in patients in homozygous and compound heterozygote groups was lower as compared to heterozygote. In other words, in patients with one mutation, the disease started later. Fever and peritonitis were frequent symptoms in patients with the M694V and E148Q mutations. However, the symptoms were less frequent in patients with the E148Q/E148Q genotype, indicating that two mutations of E148Q may be associated with a

homozygote and heterozygote groups, the most common genotypes were M694V/M694V and M694V/- and in the compound heterozygote group the most common genotype was M694V/E148Q. Allele frequencies of ten most common MEFV mutations among 415 patients were calculated. The most frequent mutation was M694V (identified in 42.05% of the alleles examined), followed by V726A (19.76%), E148Q (17.23%), and M680I (15.15%). Concurrently, we determined that R761H (1.78%) was the most frequent rare mutation in Iranian Azeri Turks patients. The frequencies of the other rare mutations were: M6941 (1.33%), F479L (0.9%), E167D (0.59%), R408Q (0.44%), P369S and A744S (0.29%), and R694I (0.14%).
moderate form of the disease. Among the five most common mutations, M694V, V726A, and M694I mutations showed significant association with fever and peritonitis in the homozygote state (P<0.01), while patients with M680I without fever and peritonitis symptoms were significantly associated with amyloidosis. We enrolled 15 homozygous patients for M680I mutation, from which, only four subjects were asymptomatic which were detected through family studies. The remaining 11 patients had amyloidosis. Statistical analysis showed that the association between the presence of M694I and M680I mutations and amyloidosis is the only significant correlation (P<0.01). A number of studies have been published about the association between MEFV mutation and the clinical signs of FMF, especially amyloidosis. Many reports on different ethnic groups revealed that amyloidosis is associated with the M694V mutation, especially in the homozygous state (12-15). However, some studies found that there is no specific correlation between genotype and the development of amyloidosis.

It is hypothesized that amyloidosis occurs in patients with FMF due to differences in patterns of the MEFV genotype. Shohat et al found a significant association between amyloidosis and the M694V mutation and observed that patients carrying other mutations did not show amyloidosis (16). Ben-Chetrit found that amyloidosis was more common in FMF patients originating from North Africa who were homozygous for the M694V mutation (17). Shinar et al observed that the M694V/M694V genotype is associated with a more severe form of the disease compared to other common genotypes in patients with FMF (18). Majeed et al found that the genotypes M694V/M694V and M694V/V726A and M694V/M694V in the heterozygous state showed a significant association with amyloidosis. Also, M694I and M680I in the heterozygous state showed a significant association with amyloidosis. However, renal amyloidosis was seen more frequently in homozygous genotypes. Despite lots of knowledge on FMF, prospective clinical studies with large numbers of patients from different ethnic groups will help us to further clarify this considerable disease.

Conclusion
In conclusion, the most frequent mutation in FMF within our study population was M694V and the most frequent genotype was M694V/M694V. Peritonitis and fever were seen in almost all genotypes with common mutations. Renal amyloidosis was observed not only in patients with the M680I/M680I genotype but also in the M680I/- and M694I/- genotypes. Also, M694I and M680I in the heterozygous state showed a significant association with amyloidosis. However, renal amyloidosis was seen more frequently in homozygous genotypes. Despite lots of knowledge on FMF, prospective clinical studies with large numbers of patients from different ethnic groups will help us to further clarify this considerable disease.

Acknowledgment
We thank all participating patients. The financial support from the Liver and Gastrointestinal Diseases Research Center of Tabriz University of Medical Sciences, Tabriz, Iran, is greatly acknowledged.

References
1. Brik R SM, Kepten I, Berant M, Gershoni-Baruch R. Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 1999; 103:70.
2. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001; 9:473-483.
3. Ozem S. Familial Mediterranean fever: revisiting an ancient disease. Eur J Pediatr 2003; 162:449-454.
4. Rawashdeh M, Majeed H. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr 1996; 55:540-544.
5. Pras E, Akseintijevich I, Gruberg L, Balov J, Prosen L, Dean M, et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med 1992; 326:1509-1513.
6. Pras M. Familial Mediterranean Fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol 1998; 27:92-97.
7. Livneh A ZD, Langevitz P, Laor A, Sohar E, Pras M Colchicine treatment of AA amyloidosis of familial Mediterranean fever: an analysis of factors aVecting outcome. Arthritis Rheum 1994; 37:1804-1811.
8. Pras E, Akseintijevich I, Levy E, Gruberg L, Prosen L, Dean M, et al. The gene causing familial Mediterranean fever maps to the short arm of chromosome 16 in Druze and Moslem Arab families. Hum Genet 1994; 94:576-577.
9. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 2000; 14:477-498.
10. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial
Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37:1804.
11. Karalou N, Yigit S, Inanir A, Inanir S, Toprak H, Oalan S. Association between sequence variations of the Mediterranean fever gene and fibromyalgia syndrome in a cohort of Turkish patients. Clin Chim Acta 2012; 43:36-40.
12. Akpolat T, Ozkaya O, Ozen S. Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene 2012; 492:285-289.
13. Atagunduz M, Tuglular S, Kantarcı G, Akoğlu E, Direskeneli H. Association of FMF-related (MEFV) point mutations with secondary and FMF amyloidosis. Nephron Clin Pract 2004; 96:131-135.
14. Ong F, Vakil H, Xue Y, Kuo J, Shah K, Lee R, et al. The M694V mutation in Armenian-Americans: a 10-year retrospective study of MEFV mutation testing for familial Mediterranean fever at UCLA. Clin Genet 2013; 84:55-59.
15. Mansour I, Delague V, Cazeneuve C, Dode C, Chouery E, Pecheux C, et al. Familial Mediterranean fever in Lebanon: mutation spectrum, evidence for cases in Maronites, Greek orthodoxes, Greek catholics, Syriacs and Chaldees and for an association between amyloidosis and M694V and M694I mutations. Eur J Hum Genet 2003; 9:51-55.
16. Shohat M, Magal N, Shohat T, Chen X, Dagan T, Minouni A, et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between met694-to-val and amyloidosis. Europ J Hum Genet 1999; 7:287-292.
17. Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis—phenotype-genotype correlation, treatment and prognosis. J Nephrol 2003; 16:431-434.
18. Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I, Koziol D, et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol 2000; 27:1703-1707.
19. Majeed HA, El-Shant H, Al-Khateeb MS, Rahalha ZA. Genotype/phenotype correlations in Arab patients with familial Mediterranean fever. Semin Arthritis Rheum. 2002; 31:371-376.
20. Mattit H, Joma M, Al-Cheikh S, El-Khateeb M, Medlej-Hashim M, Salem N, et al. Familial Mediterranean fever in the Syrian population: gene mutation frequencies, carrier rates and phenotype-genotype correlation. Eur J Med Genet 2006; 49:481-486.
21. Demirkaya E, Tunca Y, Gok F, Ozen S, Gul D. A very frequent mutation and remarkable association of R761H with M694V mutations in Turkish familial Mediterranean fever patients. Clin Rheumatol 2008; 27:729-732.
22. Solak M1, Yildiz H, Koken R, Erdogan M, Eser B, Sen T, Evirgen N, Erdem S, Arik E. Analysis of familial Mediterranean fever gene mutations in 202 patients with familial Mediterranean fever. Genet Test 2008; 3:341-344.
23. el-Garf A, Salah S, Islander I, Salah H, Amin S. MEFV mutations in Egyptian patients suffering from familial Mediterranean fever: analysis of 12 gene mutations. Rheumatol Int 2010; 30:1293-1298.
24. Jarjour R. Familial Mediterranean fever in Syrian patients: MEFV gene mutations and genotype-phenotype correlation. Mol Biol Rep 2010; 37:1-5.
25. Ozdemir O, Sezgin I, Kurtulgan H, Candan F, Kolksal B, Sumer H, et al. Prevalence of known mutations in the MEFV gene in a population screening with high rate of carriers. Mol Biol Rep 2011; 38:3195-3200.
26. Dogan H, Koca Y, Erden G, Karaaslan Y, Bozat H. Evaluating MEFV mutation frequency in Turkish familial Mediterranean fever suspected patients and gender correlation: a retrospective study. Mol Biol Rep 2012; 39:6193-6196.
27. Gunesacar R, Celik MM, Arica V, Elmacioglu S, Ozturk OH. Frequency of MEFV gene mutations in Hatay province, Mediterranean region of Turkey and report of a novel missense mutation (I247V). Gene 2014; 546:195-9.